ArticleFrontiers in pharmacology2020
Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Development of poly(vinyl alcohol)/poly(N-vinyl caprolactam)-based hydrogel-forming microneedle for transdermal delivery of captopril: fabrication, characterization and in vivo antihypertensive activity test.Drug delivery and translational research · 2026Article
- Kallikrein-Related Peptidase 4 Inhibits Laryngeal Squamous Cell Carcinoma Potentially via Involvement of the Wnt/β-Catenin Signaling Pathway.Biochemical genetics · 2026Article
- Network pharmacology approach to unravel the neuroprotective potential of natural products: a narrative review.Molecular diversity · 2026Review
- The Dynamic UPR Rheostat Orchestrates Single-Cell Plasticity in Glioblastoma.Journal of molecular neuroscience : MN · 2025Article
- Dual evaluation of Citrullus colocynthis fruit extract for anti-rheumatic activity: integrating in silico docking and in vivo murine RA model analysis.Inflammopharmacology · 2025Article
- Metagenomic profiling of gut microbime: associating their role with the advancement of diabetic nephropathy.Antonie van Leeuwenhoek · 2025Review
- The impact of climate, weather, seasonal transitions, and diurnal rhythms on gut microbiota and immune homeostasis.Antonie van Leeuwenhoek · 2025Review
- INSTIs-centered antiviral regimens for first-line treatment of HIV/AIDS: a network meta-analysis and cost-effectiveness analysis.BMC infectious diseases · 2025Article
- Identification of mungbean yellow mosaic India virus and susceptibility-related metabolites in the apoplast of mung bean leaves.Plant cell reports · 2024Article
- Early on-treatment plasma interleukin-18 as a promising indicator for long-term virological response in patients with HIV-1 infection.Frontiers in medicine · 2023Article
- Astragalus polysaccharide: a review of its immunomodulatory effect.Archives of pharmacal research · 2022Review
- Astragalus polysaccharide: a review of its immunomodulatory effect.Archives of pharmacal research · 2022Review
- Does the cytokine adsorber CytoSorbAnnals of intensive care · 2022Article
- Treatment Outcomes of HIV Infected Children After Initiation of Antiretroviral Therapy in Southwest China: An Observational Cohort Study.Frontiers in pediatrics · 2022Article
- Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics.Archives of pharmacal research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual therapy with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) has been demonstrated to be non-inferior to the triple drug regimen including LPV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) in 48-week studies. However, little is known about the long-term efficacy and drug resistance of this simplified strategy. A randomized, controlled, open-label, non-inferiority trial (ALTERLL) was conducted to assess the efficacy, drug resistance, and safety of dual therapy with LPV/r plus 3TC (DT group), compared with the first-line triple-therapy regimen containing tenofovir (TDF), 3TC plus efavirenz (EFV) (TT group) in antiretroviral therapy (ART)-naïve HIV-1-infected adults in Guangdong, China. The primary endpoint was the proportion of patients with plasma HIV-1 RNA < 50 copies/ml at week 144. Between March 1 and December 31, 2015, a total of 196 patients (from 274 patients screened) were included and randomly assigned to either the DT group (n = 99) or the TT group (n = 97). In the primary intention-to-treat (ITT) analysis at week 144, 95 patients (96%) in the DT group and 93 patients (95.9%) in the TT group achieved virological inhibition with plasma HIV-1 RNA <50 copies/ml (difference: 0.1%; 95% CI, -4.6-4.7%), meeting the criteria for non-inferiority. The DT group did not show significant differences in the mean increase in CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.